The factor XIa inhibitor asundexian combined with standard antiplatelet therapy reduced the risk for recurrent ischemic stroke compared to antiplatelet therapy alone, without increasing bleeding, phase 3 trial data show. In the OCEANIC-STROKE randomized controlled trial of more than 12,000 patients with recent noncardioembolic ischemic stroke or high-risk transient ischemic attack (TIA…
Read More
FXIa Inhibitor Hits Mark in Recurrent Stroke Prevention
